Intelligence · Essentials

Keep track of the whole cannabis market, a month before everyone else reads about it.

Nobody can read every market, so Essentials tracks all of them for you. Every development is vetted, classified and filed, the whole market is written up once a month, and the datasets, trackers and analyst library sit underneath it. You get your time back for the part that needs your judgement.

The monthly brief is read by 3,500+ cannabis professionals.

Essentials
Content HubNews DashboardM&A TrackerMonthly Brief
Analyst insights — with the data underneath
DatapackAustralia Market Datapack — the 2025 reset: record supply, a 40% price fall
Q1Q2Q3Q4Q1Q2
FlowerOilOther
SupplyrecordPrice−40%
Units dispensedrecord high▲Average unit price−40%▼Active prescribersstill climbing▲
Sources: TGA SAS-B · ODC import permits · operator disclosures
DatasetGermany: retail and wholesale cannabis pricing, 2023–2026
WebinarCannabinoid Pharma Comes of Age — full transcript and slide pack
DateCategoryMarket verticalCountry ▾Company
Canada ✓GermanyPortugal
CARegulationHealth Canada opens consultations on deregulating hemp★
CAMarketCanopy Growth Q1 FY2027: net revenue C$81.2M, up 13% YoY★
CAScienceSystematic review: CBD raises plasma availability of THC★
Deal volume by verticalCultivation 34%Pharma 27%Retail 22%Tech 17%
Deal count by countryCanadaUSAGermanyUKPortugal
Tilray → Lyphe GroupUK1.61M shares
Verano → Cannabist (AZ + VA)USUS$105M
Emblem → Ayurcann (assets)CAC$5.5M
Every month: what moved, market by market
🇺🇸USA🏛️ Regulation📈 Market🧪 Science
DEA Schedule III hearing opens; first plant-touching NYSE listings
🇩🇪Germany🏛️ Regulation📈 Market🧪 Science
Exilby wins Europe’s first cannabis-derived painkiller authorisation
🇧🇷Brazil🏛️ Regulation📈 Market🧪 Science
ANVISA widens formal access as domestic production starts
Every row carries its primary source.

What you get

Four layers of intelligence, one subscription.

Each layer answers a different question: what it means, what is underneath it, what happened, and how it compares.

The monthly brief

Read the market when it lands, not a month later.

In the first week of every month the brief lands in your inbox: what moved in every international market, written up one market at a time, with our call on what it means. Free subscribers get a summary by email, and the full edition opens on the site a month later, when many of the decisions it covers have already been taken.
Reading it free, today
The previous edition
The newest full edition on the open web. It describes a market that has already moved on.
Read it →
Five gates, 270–412 sources, every edition.
01Retrieve, and account for everythingEvery source in scope is pulled and logged, so nothing is missed by accident.
02Read the whole month before placing anythingNo market is written up until the full month is in view — that is what makes a ranking possible.
03Verify against the article, not the headlineEach claim is checked against the underlying piece, filing or dataset.
04Rank by what actually changedPlacement follows materiality, not volume of coverage.
05Then look again, independentlyA second sweep of every tier-1 and tier-2 source, run fresh.
2026 so far. What the year has meant in 60 markets, on the brief’s three tracks: regulation, market and science. Only the stories that changed something, each from the edition it ran in.
🇲🇹 Malta2026 so far
The club model was tightened and widened in the same year, and its critics are getting louder.
🇷🇴 Romania2026 so far
A long-standing hemp grower sold up, and Romanian researchers kept publishing.
🇸🇮 Slovenia2026 so far
Voters and Parliament said yes, and implementation has barely started.
🇷🇸 Serbia2026 so far
Serbia surfaced through a diversion ring next door and a hemp remediation study.
🇳🇴 Norway2026 so far
Patient access shrank, and patient groups asked for a pilot programme.
🇨🇷 Costa Rica2026 so far
A small export business reached Europe while the home market waits for testing capacity.
🇸🇽 Sint Maarten2026 so far
An exclusive concession was granted before any cannabis law existed, and Parliament is now asking to see it.
🇵🇪 Peru2026 so far
Hemp rules and medical access are both stuck behind missing regulations.
🇳🇵 Nepal2026 so far
Reform moved at provincial level, where Gandaki passed the country’s first cannabis law.
🇰🇪 Kenya2026 so far
The year’s one question was whether Rastafari could use cannabis as a sacrament, and the court said no.
📈Market
Nothing critical in the 2026 briefs so far.
🧪Science
Nothing critical in the 2026 briefs so far.
🇸🇿 Eswatini2026 so far
Seizures on the South African border dominated until a draft bill and the first hemp trials arrived.
🇿🇲 Zambia2026 so far
Zambia is taking cannabis out of a military monopoly and preparing hemp licences.
🇳🇦 Namibia2026 so far
Two court challenges to prohibition failed, and reform was handed to the law-review commission.
🇱🇧 Lebanon2026 so far
The regulator finally exists, five years after the law, and the growing season keeps starting without its licences.
🇮🇷 Iran2026 so far
Iran appears in the briefs for its plant genetics.
🏛️Regulation
Nothing critical in the 2026 briefs so far.
📈Market
Nothing critical in the 2026 briefs so far.
🇦🇪 United Arab Emirates2026 so far
A hemp framework took effect in January and still awaits its implementing rules.
60 markets and 314 stories, through the October 2026 edition. Each story opens the brief it ran in. The October stories are in the edition Essentials subscribers already have. Start tracking →

The content hub

Every insight in the hub comes with the evidence behind it.

Each analyst insight carries the material the published version leaves out: the dataset it was built from, the reconciliation behind the headline figure, and the primary documents themselves. Around one in four is published openly, and the rest stay in the hub.
Free article
In the hub
The chart
chart
→
interactive dashboard
The analysis
summary
→
full angle
The numbers
1headline figure
→
dataset + reconciliation
The sources
key links
→
full attribution + method

Webinars

Every session, transcribed and analysed for you.

We record each session with operators, clinicians and researchers who work inside the markets we cover. You don’t have to watch an hour of video: the full transcript is in the hub, already worked through, with the slide pack beside it. There are 13 sessions in the hub, and the most recent are below.

The dashboard

Search the whole market six different ways.

Roughly 520 developments were vetted, summarised and classified every month across the first half of 2026. Each one has its primary source attached, and you can filter them by date, category, market vertical, country and company.
Content Hub
Analyst insights, datapacks and webinar recaps — each with the data underneath it.
DatapackAustralia — the 2025 resetRecord supply against a 40% unit-price fall, with the quarterly series attached.
DatasetGermany pricing 2023–2026Retail and wholesale, three years, reconciled across sources.
TranscriptCannabinoid pharma, analysedThe full session transcript, already worked through, with the slide pack.
News Dashboard
Every classified development, filterable five ways.
DE · RegulationExilby authorisationEurope’s first authorisation for a cannabis-derived painkiller.
CA · MarketHigh Tide record revenueThe quarter that proved Canadian retail can be profitable at scale.
FR · ScienceU.Cannabis, 1,971 patientsThe largest patient cohort yet on cannabis and opioid reduction.
Regulatory
Laws, reforms, consultations and enforcement, market by market.
DEGKV draft would strip flower from reimbursementThe reimbursement fight that decides whether German flower stays funded.
AUTGA hardens advertising enforcementEnforcement, not rulemaking — the risk sits with how you advertise.
THHouse committee reviews relisting cannabisThe reversal that would put Thailand’s market back under prescription.
Market
Sales, imports, prescriptions, patients and company financials.
CAPre-rolls overtake flower at C$1.43bnFormat share moved before volume did — a leading indicator, not a lagging one.
UK2025 imports 30,061 kg; Canada supplies 70–80%Import dependence with a single dominant supplier is a concentration risk.
THCumulative exports 201,658 kgExport scale is now the argument for Thai supply, not domestic demand.
Science
Trials, studies, R&D and the evidence base.
FRU.Cannabis, 1,971 patients: opioid use fallsReal-world evidence at a scale regulators will actually read.
AUSydney RCT: high-dose CBD, pain 3.82 vs 4.36A controlled trial, so the effect size can be argued in a submission.
DECannabis Act survey, 11,471 usersLegal sourcing rose from 23.5% to 88.4% after the Act.
M&A Tracker
Deals, filings and consideration — who bought what, and for how much.
Tilray → LypheUK · 1.61M sharesVertical integration into UK prescribing, paid in stock.
Emblem → AyurcannCA · C$5.5MMulti-state consolidation continuing through the Schedule III window.
Verano → CannabistUS · US$105MAn asset purchase, not a going concern — the distinction matters.

Who uses it

Three jobs professionals hire Essentials to do.

These are the questions subscribers bring to Essentials, and the part of the subscription that answers each one.
🌍
Job 1
Stay current across every market
“What changed this month, and does it matter to me?”
For consultants, regulatory affairs, investors and independent analysts
How Essentials answers it ↑
You’ll use
Monthly briefNews dashboardRegulatory tracker
To
Scan 30 to 50 markets in one read
Check what changed in a country before a call
Catch a consultation before it closes
🔎
Job 2
Build and defend a point of view
“What’s the real story behind the headline?”
For analysts, strategists, advisors and journalists
How Essentials answers it ↑
You’ll use
Content hubDatasetsPrimary documents
To
Pull the dataset behind a headline figure
Trace a number back to its source
Reuse a chart with the data attached
📣
Job 3
Brief clients, teams and stakeholders
“How do I get other people up to speed, fast?”
For business development, comms, founders and consultants
How Essentials answers it ↑
You’ll use
Monthly briefWebinar transcriptsSlide packs
To
Turn the month into a client update
Lift slides for an internal briefing
Send a colleague the one entry they need

Pricing

Read the market a month early for €14.20 a month.

You get the brief in the first week of the month, and everything it is built on for the rest of it. Pay yearly and two months are free.
Monthly Brief
Free
A summary by email
Essentials
€14.20/month
or €142 a year, two months free
Decide
€1,420/year
+ €420 a year per extra seat
A summary of the month by email
✓
✓
✓
The full brief, the day it is written
A month later
✓
✓
Content hub: insights with their datasets and sources
✕
✓
✓
Webinar transcripts and slide packs
✕
✓
✓
News dashboard, filterable five ways
✕
✓
✓
M&A tracker
✕
✓
✓
Every company, country, deal and filing cross-linked
✕
✕
✓
Built for a team
✕
✕
✓
Self-serve checkout · cancel anytime

Questions

The things people ask before subscribing.

Three things. The first is timing: the full monthly brief reaches you the day it is written, while free subscribers get a summary by email and the open site gets the full edition a month later. The second is depth: the content hub holds every analyst insight with its dataset, its reconciliation and its primary sources, and only around one in four of those is published openly. The third is the dashboard: 10,000+ classified news items you can filter by date, category, market vertical, country and company, with the webinar transcripts, their slide packs and the M&A tracker alongside.
Each edition writes up between 30 and 50 countries, one at a time. A country entry carries a line on what the month meant for that market, up to three key figures with the primary source attached, flags for regulation, market and science, and a note on what is coming next. There are more than 30 editions in the archive.
Free subscribers get a summary of the month by email, and each full edition opens on the site a month after subscribers receive it. Essentials gives you the full edition straight away, with the hub, the dashboard and the trackers behind it.
A newsletter is usually one editor’s pick of the week. In Essentials every development is vetted, summarised and classified by market and topic, with its primary source attached, so you can still search the archive months later and find what you need.
Essentials keeps one professional up to date across every market. Decide is built for a team that has to make a decision: every company, country, deal and filing is cross-linked and reconciled, so you can follow a question from one record to the next.
It is updated continuously. Roughly 520 classified items were added each month across the first half of 2026, and the brief comes on top of that.
Each edition covers between 30 and 50 countries, and coverage is deepest in the US, Germany, Canada, the UK and Australia. If your market is thinly covered, tell us, because coverage follows what subscribers ask for.
Yes. Checkout is self-serve and you can cancel at any time.
It costs less than a couple of trade-press subscriptions and it replaces hours of scanning every week. If you pay yearly it is €142, which gives you two months free.

Read every edition the week it is written, with the data behind it, for €14.20 a month.